SBRT for recurrent head and neck cancer

Micro-Mini & Nano-Dosimetry & Innovative Technologies in Radiation Therapy

Garg, M.^1 ; Kabarriti, R.^1 ; Baliga, S.^1 ; Guha, C.^1 ; Tome, W.^1 ; Kalnicki, S.^1

Montefiore Medical Center, Albert Einstein College of Medicine, New York, United States^1

关键词: Cetuximab;    Clinical settings;    Head-and-neck cancer;    Normal tissue;    Reirradiation;    Stereotactic body radiation therapy;    Systemic therapy;    Treatment modality;   

Others  :  https://iopscience.iop.org/article/10.1088/1742-6596/777/1/012025/pdf
DOI  :  10.1088/1742-6596/777/1/012025

来源: IOP

【 摘 要 】

The management of patients with recurrent head and neck cancers is complex. Concerns over toxicity with re-irradiation have limited its use in the clinical setting. Stereotactic Body Radiation Therapy (SBRT) has emerged as a highly conformal and precise type of radiotherapy and has the advantage of sparing normal tissue. Although SBRT is an attractive treatment modality, its use in the clinic is limited, given the technically challenging nature of the procedure. In this review, we attempt to provide a comprehensive overview of the role of re-irradiation in patients with recurrent head and neck cancers, with particular attention to the advent of SBRT and its use with systemic therapies such as cetuximab.